These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 39055758

  • 1. How accurate are NT-proBNP, ANP, and cTnI levels in diagnosing dogs with myxomatous mitral valve disease?
    Chanmongkolpanit K, Riengvirodkij N, Channgam P, Kaenchan P, Buayam W, Janhirun Y, Phonarknguen R, Tansakul M, Sakcamduang W.
    Open Vet J; 2024 Jun; 14(6):1426-1441. PubMed ID: 39055758
    [Abstract] [Full Text] [Related]

  • 2. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
    Wolf J, Gerlach N, Weber K, Klima A, Wess G.
    Vet Clin Pathol; 2013 Jun; 42(2):196-206. PubMed ID: 23614733
    [Abstract] [Full Text] [Related]

  • 3. Comparison of N-terminal pro-atrial natriuretic peptide and three cardiac biomarkers for discriminatory ability of clinical stage in dogs with myxomatous mitral valve disease.
    Ogawa M, Hori Y, Kanno N, Iwasa N, Toyofuku T, Isayama N, Yoshikawa A, Akabane R, Sakatani A, Miyakawa H, Hsu HH, Miyagawa Y, Takemura N.
    J Vet Med Sci; 2021 Apr 24; 83(4):705-715. PubMed ID: 33551383
    [Abstract] [Full Text] [Related]

  • 4. Plasma humanin as a prognostic biomarker for canine myxomatous mitral valve disease: a comparison with plasma NT-roBNP.
    Mangkhang K, Punyapornwithaya V, Tankaew P, Pongkan W, Chattipakorn N, Boonyapakorn C.
    Pol J Vet Sci; 2018 Dec 24; 21(4):673-680. PubMed ID: 30605282
    [Abstract] [Full Text] [Related]

  • 5. Effect of Pimobendan on NT-proBNP and c troponin I before and after a submaximal exercise test in dogs with preclinical mitral valve disease without cardiomegaly - a randomised, double-blinded trial.
    Iwanuk N, Nolte I, Wall L, Sehn M, Raue J, Pilgram A, Rumstedt K, Bach JP.
    BMC Vet Res; 2019 Jul 09; 15(1):237. PubMed ID: 31288807
    [Abstract] [Full Text] [Related]

  • 6. Brain-natriuretic peptide and cyclic guanosine monophosphate as biomarkers of myxomatous mitral valve disease in dogs.
    Moesgaard SG, Falk T, Teerlink T, Guðmundsdóttir HH, Sigurðardóttir S, Rasmussen CE, Olsen LH.
    Vet J; 2011 Sep 09; 189(3):349-52. PubMed ID: 20822939
    [Abstract] [Full Text] [Related]

  • 7. N-terminal pro-B-type natriuretic peptide levels in normotensive and hypertensive dogs with myxomatous mitral valve disease stage B.
    Jang IS, Yoon WK, Choi EW.
    Ir Vet J; 2023 Feb 08; 76(1):3. PubMed ID: 36755290
    [Abstract] [Full Text] [Related]

  • 8. Diagnostic value of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and their correlation with lipoproteins in dogs with myxomatous mitral valve disease.
    Khaki Z, Nooshirvani P, Shirani D, Masoudifard M.
    BMC Vet Res; 2022 Dec 23; 18(1):448. PubMed ID: 36564735
    [Abstract] [Full Text] [Related]

  • 9. DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study.
    Borgarelli M, Ferasin L, Lamb K, Bussadori C, Chiavegato D, D'Agnolo G, Migliorini F, Poggi M, Santilli RA, Guillot E, Garelli-Paar C, Toschi Corneliani R, Farina F, Zani A, Dirven M, Smets P, Guglielmini C, Oliveira P, Di Marcello M, Porciello F, Crosara S, Ciaramella P, Piantedosi D, Smith S, Vannini S, Dall'Aglio E, Savarino P, Quintavalla C, Patteson M, Silva J, Locatelli C, Baron Toaldo M.
    J Vet Cardiol; 2020 Feb 23; 27():34-53. PubMed ID: 32032923
    [Abstract] [Full Text] [Related]

  • 10. Lowered N-terminal pro-B-type natriuretic peptide levels in response to treatment predict survival in dogs with symptomatic mitral valve disease.
    Wolf J, Gerlach N, Weber K, Klima A, Wess G.
    J Vet Cardiol; 2012 Sep 23; 14(3):399-408. PubMed ID: 22858663
    [Abstract] [Full Text] [Related]

  • 11. Prognostic factors in dogs with presumed degenerative mitral valve disease attending primary-care veterinary practices in the United Kingdom.
    Mattin MJ, Boswood A, Church DB, Brodbelt DC.
    J Vet Intern Med; 2019 Mar 23; 33(2):432-444. PubMed ID: 30357909
    [Abstract] [Full Text] [Related]

  • 12. NT-proBNP, NT-proANP and cTnI concentrations in dogs with pre-capillary pulmonary hypertension.
    Kellihan HB, Mackie BA, Stepien RL.
    J Vet Cardiol; 2011 Sep 23; 13(3):171-82. PubMed ID: 21835711
    [Abstract] [Full Text] [Related]

  • 13. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
    Hezzell MJ, Block CL, Laughlin DS, Oyama MA.
    J Vet Intern Med; 2018 Sep 23; 32(5):1509-1516. PubMed ID: 30216549
    [Abstract] [Full Text] [Related]

  • 14. The combined prognostic potential of serum high-sensitivity cardiac troponin I and N-terminal pro-B-type natriuretic peptide concentrations in dogs with degenerative mitral valve disease.
    Hezzell MJ, Boswood A, Chang YM, Moonarmart W, Souttar K, Elliott J.
    J Vet Intern Med; 2012 Sep 23; 26(2):302-11. PubMed ID: 22369312
    [Abstract] [Full Text] [Related]

  • 15. Biologic variability in NT-proBNP and cardiac troponin-I in healthy dogs and dogs with mitral valve degeneration.
    Ruaux C, Scollan K, Suchodolski JS, Steiner JM, Sisson DD.
    Vet Clin Pathol; 2015 Sep 23; 44(3):420-30. PubMed ID: 26108974
    [Abstract] [Full Text] [Related]

  • 16. Predictive value of natriuretic peptides in dogs with mitral valve disease.
    Tarnow I, Olsen LH, Kvart C, Hoglund K, Moesgaard SG, Kamstrup TS, Pedersen HD, Häggström J.
    Vet J; 2009 May 23; 180(2):195-201. PubMed ID: 18675567
    [Abstract] [Full Text] [Related]

  • 17. Clinical utility of serum N-terminal pro-B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity.
    Oyama MA, Fox PR, Rush JE, Rozanski EA, Lesser M.
    J Am Vet Med Assoc; 2008 May 15; 232(10):1496-503. PubMed ID: 18479239
    [Abstract] [Full Text] [Related]

  • 18. Plasma N-terminal pro-B-type natriuretic peptide concentration helps to predict survival in dogs with symptomatic degenerative mitral valve disease regardless of and in combination with the initial clinical status at admission.
    Serres F, Pouchelon JL, Poujol L, Lefebvre HP, Trumel C, Daste T, Sampedrano CC, Gouni V, Tissier R, Hawa G, Chetboul V.
    J Vet Cardiol; 2009 Dec 15; 11(2):103-21. PubMed ID: 19850546
    [Abstract] [Full Text] [Related]

  • 19. Plasma atrial natriuretic peptide and N-terminal pro B-type natriuretic peptide concentrations in dogs with right-sided congestive heart failure.
    Kanno N, Hori Y, Hidaka Y, Chikazawa S, Kanai K, Hoshi F, Itoh N.
    J Vet Med Sci; 2016 May 03; 78(4):535-42. PubMed ID: 26607133
    [Abstract] [Full Text] [Related]

  • 20. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J, Lord PF, Höglund K, Ljungvall I, Jöns O, Kvart C, Hansson K.
    J Vet Intern Med; 2013 May 03; 27(6):1452-62. PubMed ID: 24128373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.